Eli Lilly and Company (NYSE: LLY) and Morphic Holding, Inc. (NASDAQ: MORF) today announced a definitive agreement for Lilly to acquire Morphic, a biopharmaceutical company developing oral integrin therapies for treatment of serious chronic diseases.
Eli Lilly, Sanofi Merck, AstraZeneca's and Roche are included in this Analyst Blog.
Tesla drove the S&P 500 and Nasdaq to highs, though small caps fell for the week. Cooling economic data raised rate-cut hopes.